HIKAL vs JBCHEPHARM: Stock Comparison
Hikal Limited vs JB Chemicals & Pharmaceuticals Limited
Live data: 22 July 2026, 3:03 PM IST • Source: NSE and company filings
JB Chemicals & Pharmaceuticals Limited is the larger company by market capitalisation. Hikal Limited shows a lower P/E and faster revenue growth, while JB Chemicals & Pharmaceuticals Limited shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of Hikal Limited and JB Chemicals & Pharmaceuticals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | HIKAL | JBCHEPHARM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | HIKAL | JBCHEPHARM |
|---|---|---|
| Live Price | ₹213.4 | ₹2,408.9 |
| Day Change | -5.05% | -3.87% |
| Volume | 3.51 L | 47.79 L |
| 52-Week High | ₹343.85 | ₹2,525.5 |
| 52-Week Low | ₹146.25 | ₹1,638.5 |
| Distance from 52W High | -37.94% | -4.62% |
Valuation
| Metric | HIKAL | JBCHEPHARM |
|---|---|---|
| Market Cap | ₹2,637 Cr | ₹38,731 Cr |
| P/E Ratio | -56.64x | 54.59x |
| P/B Ratio | 2.31x | 9.31x |
| EPS | ₹-3.95 | ₹44.49 |
| Book Value | ₹97.4 | ₹259.05 |
| Dividend Yield | 0.44% | 1.19% |
Growth
| Metric | HIKAL | JBCHEPHARM |
|---|---|---|
| Revenue Growth (TTM YoY) | 37.3% | -4.8% |
| EPS Growth (TTM YoY) | 68.3% | -31% |
| Qtr Sales Growth | -5.97% | -4.77% |
| Qtr Profit Growth | 22.5% | -17% |
Profitability & Leverage
| Metric | HIKAL | JBCHEPHARM |
|---|---|---|
| ROE | 2.95% | 18.9% |
| ROCE | 3.52% | 25.4% |
| Net Margin | -2.88% | 17.1% |
| Operating Margin | 12.9% | 26.7% |
| Debt to Equity | 0.57x | 0x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | HIKAL | JBCHEPHARM |
|---|---|---|
| Promoter Holding | 68.85% | 48.8%▲ 48.8 pp |
| FII Holding | 1.43%▼ 0.87 pp | 16.33%▲ 1.45 pp |
| DII Holding | 7.2%▲ 0.15 pp | 21.38%▼ 1.98 pp |
| Public Holding | 22.52%▲ 0.73 pp | 13.48%▼ 0.74 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Hikal Limited and JB Chemicals & Pharmaceuticals Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.